You are here
P&T October 2015
Congress may be about to rein in the 340B drug program, which lets safety-net hospitals and community clinics use outpatient prescription sales to generate revenue. The Health Resources and Services Administration, which runs the program, has published draft guidance to clarify issues raised by federal watchdog agencies.
This installment of a five-part series reviews the role of nondopaminergic pharmacotherapies and adjunctive options—such as monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors, and anticholinergic agents—in managing Parkinson’s disease. Nonpharmacological treatments are also explored.
P&T committees will play a key role in driving the adoption of biosimilars, which have unique characteristics compared with small-molecule generic drugs. Key elements of formulary review will include clinical parameters, product characteristics, and institutional considerations, which are among the issues covered in this article.
The coordination of care as patients move from one health care setting to another is crucial to treatment, but breakdowns in the process lead to poor transitions, fragmented care, hospital readmissions, and increased costs. This article discusses evidence-based strategies for improving communication and reducing readmissions.
Physician dispensing in offices and clinics raises concerns.
The FDA’s plan for interstate compounding jars hospitals.
FDA approvals, drug indications, and updates
Alirocumab (Praluent) for high cholesterol; flibanserin (Addyi) for sexual desire disorder in women; daclatasvir (Daklinza) for chronic hepatitis C virus (HCV) genotype 3 infection; and ombitasvir/paritaprevir/ritonavir (Technivie) for genotype 4 HCV infection without cirrhosis.
Edoxaban (Savaysa): A factor Xa inhibitor